Business Wire

IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development

15.1.2020 20:10:00 EET | Business Wire | Press release

Share

DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to

$23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program. The goal of the project is to develop sequence-controlled polymers as the basis for deployable storage technologies that can eventually scale into the exabyte regime and beyond with reduced physical footprint, power and cost requirements relative to conventional storage technologies.

The Molecular Encoding Consortium is led by the Laboratory of Dr. Robert Nicol at the Broad Institute of MIT and Harvard and includes DNA Script and Professor Donhee Ham’s Research Group at Harvard University. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument over the 4-year duration of the program. The consortium plans to collaborate with Illumina to leverage its sequencing-by-synthesis (SBS) technologies for accurate, low cost decoding.

Massive amounts of digital data are generated every day, and emerging technologies such as autonomous cars and artificial intelligence will further increase the need for data storage at unprecedented scales. This causes major challenges to private and public organizations, which currently rely on exabyte-scale data centers that have large footprints, consume megawatts of power and cost hundreds of millions of dollars to build, operate and maintain over their lifetimes. It is expected that the anticipated growth in data storage requirements cannot be addressed by current resource-intensive technologies. Nucleic acid-based systems hold promise to store this information with radically reduced physical footprints, power and cost requirements.

This technology is not mature yet and will require extensive development to be ready to use. IARPA has therefore launched the MIST program to fund initiatives that could turn molecular-based data storage into reality. The Molecular Encoding Consortium is one of these funded projects.

“This contract with IARPA, which is part of the Office of the Director of National Intelligence, in partnership with prestigious partners such as the Broad Institute and Harvard University is a strong recognition of DNA Script’s results and leadership in developing enzymatic template-free nucleic acid synthesis,” said Dr. Thomas Ybert, CEO of DNA Script. “However, it is only the beginning of this ambitious project, which will require us to push current technological limits to bring to life our cutting-edge technology while also delivering an operational solution to one of the most important challenges of our time.”

“This project at the intersection of molecular biology, physics, chemistry, information theory and electrical engineering leverages the multi-disciplinary capabilities of our laboratory, our exceptional consortium partners and the collaborative nature of our Institute,” said Dr. Robert Nicol, Senior Director of Technology Development at the Broad Institute and the consortium’s Principal Investigator. “The objectives set out by IARPA for this four-year program are ambitious and will require scientific innovations, as well as robust and scalable technologies.”

“The Molecular Encoding Consortium integrates the different experiences and expertise of these leading institutions,” said Dr. Donhee Ham, the Gordon McKay Professor of Electrical Engineering and Applied Physics at Harvard University. “My research group will bring expertise in the interface of solid-state electronic chips and biological systems. I am looking forward to working with the consortium team in combining silicon integrated circuit technology with molecular biology and electrochemistry to tackle this very interesting problem.”

“DNA is the ideal way to store information for long periods of time,” said Dr. Mostafa Ronaghi, Chief Technology Officer of Illumina. “We are excited by the opportunity to collaborate with the early pioneers involved in this project and having our SBS chemistry and instruments used to decode the digital information.”

About IARPA
IARPA invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the Intelligence Community. Additional information on IARPA and its research may be found on www.iarpa.gov.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new diagnostics, therapeutics, sustainable chemicals production, improved crops and data storage solutions. www.dnascript.co

About the Dr. Donhee Ham Research Group
Established in 2002, one of the major intellectual focuses of Donhee Ham’s research group has been on directly interfacing silicon integrated circuits with biological systems for applications in neuroscience, neurotechnology, and biomolecular spectroscopy. Notably, his group at Harvard Applied Physics in collaboration with Dr. Hongkun Park’s group at Harvard Chemistry has recently developed a silicon electronic chip with a surface nanoelectrode array that can copy the synaptic connectivity of thousands of connected mammalian neurons. http://ham.seas.harvard.edu

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact in the US for DNA Script
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com

Press contact in Europe for DNA Script
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

DNA Script Contact
publicrelations@dnascript.com

Illumina Contact
Jen Carroll
jcarroll@illumina.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye